Charles Schwab Investment Management Inc. increased its holdings in Disc Medicine, Inc. (NASDAQ:IRON – Free Report) by 2.8% ...

HC Wainwright reaffirmed their buy rating on shares of Mind Medicine (MindMed) (NASDAQ:MNMD – Free Report) in a research ...

Reports FY24 revenue $2.983M vs $0 last year. “Entering 2025 marks the next chapter for Prime Medicine (PRME) as we look to share initial data for our most advanced product candidate ...

Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on IRON: Disc Medicine NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Disc Medicine, Inc. (IRON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

Spun off from Labcorp in 2023 to focus exclusively on clinical research services, Fortrea (NASDAQ:FTRE) is a contract research organization that helps pharmaceutical, biotech, and medical device ...

As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the ...

Johnson & Johnson has announced a $55 billion investment in the U.S. over the next four years. This move will boost American ...

Fintel reports that on March 21, 2025, Leerink Partners downgraded their outlook for Elevation Oncology (NasdaqGS:ELEV) from ...